Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer

Complete Title: A Phase I Dose Escalation Trial of Alpha-tocopheryloxyacetic Acid (alpha-TEA) in Patients with Treatment Refractory HER2+ Metastatic Breast Cancer
Trial Phase: I
Investigator: William Gwin

This phase I trial studies the side effects and best dose of alpha-TEA when given together with trastuzumab and to see how well they work for the treatment of HER2+ breast cancer that does not respond to treatment (refractory) and has spread to other places in the body (metastatic). Anti-cancer treatment, such as alpha-TEA, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab is a form of "targeted therapy" because it works by attaching itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body`s immune system. Giving alpha-TEA and trastuzumab may work better for the treatment of breast cancer compared to usual treatments.

Keywords:
  • Breast Cancer
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Checklist icon

Join a Clinical Trial

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Contact Us

If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.

Adult
I
William Gwin
RG1004302
NCT04120246
A Phase I Dose Escalation Trial of Alpha-tocopheryloxyacetic Acid (alpha-TEA) in Patients with Treatment Refractory HER2+ Metastatic Breast Cancer
Breast Cancer